Brorphine
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Brorphine (3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one) is a synthetic opioid of the piperidine benzimidazolone class. Its potency sits roughly ten times that of morphine, placing it well above common opioids but several-fold below fentanyl.[1] It activates opioid receptors in the brain, suppressing pain signals and slowing the drive to breathe.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, fentanyl, hydromorphone +3 moremorphine, fentanyl, hydromorphone, methadone, heroin, oxycodone show less
Researchers first described brorphine in 2018, designing it as a potentially safer analgesic.[3] It was taken directly from published research into illicit manufacture — by mid-2020 it was the dominant non-fentanyl novel synthetic opioid in the United States, linked to over 100 deaths.[4][5] US federal scheduling in 2021 and international scheduling in 2022 reduced its presence in the drug supply.
Subjective effects include deep pain suppression, euphoria, heavy sedation, warmth, and complete suppression of distress. The experience is defined by what it removes — pain, anxiety, and awareness of the body fade into a quiet, weighted calm. Nausea, respiratory depression, and loss of consciousness are characteristic unwanted effects.
Brorphine carries high abuse liability, and standard naloxone doses may not fully reverse its respiratory depression.[6] Every documented death involved fentanyl and benzodiazepines — brorphine has not been found in illicit supply as a standalone drug.[7] No controlled human studies exist; all data come from forensic casework and animal models, leaving dose thresholds and dependence timelines entirely unknown.
History[edit]
Discovery
The piperidine benzimidazolone scaffold traces to a 1967 Janssen Pharmaceutica patent.[8] Brorphine itself was first described in 2018 by Kennedy et al. as part of a series designed to produce opioids with reduced respiratory depression.[3] That safety rationale failed — subsequent testing found no meaningful difference from conventional opioids.[2][6]
Illicit emergence and mortality
Brorphine was taken directly from the Kennedy et al. publication and manufactured for illicit sale.[4][9] It appeared in Canadian markets by April 2019 and US seizures by June 2019.[5][10] When a competing novel opioid was emergency-scheduled in mid-2020, brorphine filled the gap — becoming the dominant non-fentanyl synthetic opioid in the US and linked to over 100 deaths that year.[7][11]
Scheduling and decline
The DEA placed brorphine in Schedule I in March 2021, citing at least 21 US fatalities,[5] with permanent placement in March 2023.[12] International scheduling under the UN Single Convention followed in March 2022.[13] Post-scheduling hair analysis surveys found no brorphine detections, suggesting effective supply disruption.[14]
The name "brorphine" derives from its bromine substituent combined with the parent compound orphine (the unsubstituted piperidine benzimidazolone). Forum discussions of brorphine preceded laboratory detections — a pattern confirmed by Barenholtz et al.,[15] which helped establish user-generated online content as an early warning signal for emerging novel synthetic opioids. At least five structural analogues have since been reported to the UNODC.[16]
Chemistry[edit]
Structural class
Brorphine belongs to the piperidine benzimidazolone class of synthetic opioids — structurally distinct from fentanyl and from the nitazene family, despite sharing a benzimidazolone ring with the latter.[6][17] The compound was first described in 2018 as part of a medicinal chemistry series.[3] The bromine atom on its side chain is what distinguishes brorphine from its close analogues chlorphine, fluorphine, and iodorphine.[18]
Molecular identity
| Molecular formula | C₂₀H₂₂BrN₃O |
| Molecular weight | 400.3 g/mol (free base); ~436.8 g/mol (HCl salt) |
The molecule is built from three connected systems: a benzimidazol-2-one ring, a central piperidine ring, and a 1-(4-bromophenyl)ethyl side chain.[8][11]
Pharmacology[edit]
Mechanism of action
Brorphine is a full opioid agonist — it activates opioid receptors in the brain and spinal cord with high efficacy, producing the full opioid cascade: pain suppression, sedation, and respiratory depression.[2][6]
It was designed to favor one signaling pathway over another — a strategy intended to reduce respiratory depression. That rationale failed: testing found no meaningful difference from conventional opioids like hydromorphone, and its maximum receptor effect exceeds hydromorphone by more than 2.6-fold.[2][6][3]
Pharmacokinetics
No controlled human pharmacokinetic studies exist. The compound class is reported to have long half-lives and high brain penetration.[3] Fourteen distinct metabolites have been identified in human samples,[19] and forensic blood concentrations in fatal cases ranged from 0.1 to 10 ng/mL — no independent lethal concentration can be established, as every case involved co-intoxicants.[7]
Neuroscience[edit]
Where it acts
Brorphine activates opioid receptors concentrated in the brain's reward and pain-processing centers. inferred In reward circuits, this releases dopamine — producing the euphoria and reinforcement characteristic of potent opioids.[1] The compound's high receptor efficacy[2] means both pathways are engaged intensely at the same time.
Why it matters
The most dangerous property is its effect on breathing. Opioid receptors in the brainstem directly control the rhythm that drives respiration — intense activation slows breathing to a stop. Animal studies found that even high-dose naloxone could not fully reverse respiratory depression for some compounds in this class.[6]
The absence of signaling bias[2] means brorphine produces tolerance and physical dependence in the same pattern as conventional opioids — not the reduced dependence once anticipated from this design approach.
The mechanism behind incomplete naloxone reversal in this compound class is unexplained — possible explanations include non-opioid receptor contributions, unusually persistent receptor binding, or active metabolites with distinct pharmacology.[6] Whether the 14 identified metabolites[19] possess their own opioid activity is unknown. No brain penetration measurements specific to brorphine have been published, despite class-level reports of high CNS entry.[3]
Subjective Effects[edit]
No controlled studies have characterized brorphine's subjective experience in isolation.[7] Every documented human exposure involved concurrent fentanyl, making the experience impossible to separate from its polydrug context. Based on its pharmacological profile, the experience is expected to be dominated by deep opioid warmth — pain gone, distress gone, awareness narrowing to a quiet, weighted drift.
Compared to Fentanyl, the compound class is reported to have longer duration and higher brain penetration,[3] suggesting a more sustained and deeply sedating character. Compared to morphine, brorphine's roughly tenfold greater potency[1] means the experience arrives at far smaller doses, with a steep dose-response curve.
Effect Grid
Common doses produce the full opioid experience: pronounced euphoria, strong pain suppression, significant sedation, and marked anxiety suppression. Cognitive euphoria accompanies a warm, enveloping body high with tactile euphoria. Thought deceleration and focus suppression are prominent. Emotional suppression noticeably dampens affective reactivity.
Bodily heaviness is substantial. Constipation, pupil constriction, and nausea are expected. Respiratory depression is pharmacologically active at this level. Motor control impairment makes coordination unreliable. Physical fatigue and sociability suppression encourage withdrawal from activity.
No human dosing data exist for brorphine. This compound class exhibits incomplete naloxone reversal — emergency reversal may require higher or repeated naloxone doses compared to fentanyl or heroin overdoses.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Proprioceptive distortion · Visual haze / noise · Visual processing suppression
Muscle relaxation · Bodily heaviness · Body high · Breathing alteration · Appetite suppression · Dizziness · Nausea · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Abnormal heartbeat · Dry mouth · Excessive sweating · Sexual arousal suppression · Heart rate perception changes · Nasal congestion · Temperature dysregulation · Vomiting · Watery eyes · Yawning · Nystagmus (eye wobbles) · Involuntary body movements · Bodily dissociation
Breathing alteration · Appetite suppression · Dizziness · Nausea · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Dry mouth · Excessive sweating · Sexual arousal suppression · Heart rate perception changes · Nasal congestion · Temperature dysregulation · Vomiting · Watery eyes · Yawning · Nystagmus (eye wobbles) · Involuntary body movements · Bodily dissociation
Information processing suppression · Thought deceleration · Analysis suppression · Cognitive euphoria · Motivation suppression · Creativity suppression · Language suppression · Memory suppression · Confusion · Suggestibility enhancement · Thought disorganization · Delusions of sobriety · Cognitive dysphoria · Amnesia · Delirium
Cognitive euphoria · Motivation suppression · Creativity suppression · Language suppression · Memory suppression · Confusion · Thought disorganization · Delusions of sobriety · Cognitive dysphoria · Amnesia · Delirium
Social disconnection · Sociability enhancement · Depersonalization · Derealization · Cognitive disconnection
Cognitive disconnection
Timeline
First awareness of opioid activity — subtle warmth and faint mood lift. Effects may be difficult to distinguish from placebo at this stage.
Body high develops with spreading warmth and emerging anxiolysis. Pain suppression and pupil constriction become noticeable. Mild nausea may appear.
Full opioid state — euphoria, sedation, and pain suppression reach maximum. Respiratory depression is pharmacologically active. Nodding may occur at higher doses.
Effects sustain at reduced intensity. Sedation and bodily heaviness persist. Cognitive impairment and emotional suppression continue.
Gradual return toward baseline. Residual sedation, constipation, and pupil constriction linger. Mood may flatten as euphoria fades.
Subtle residual effects — mild sedation, constipation, and mood changes may persist for hours given the compound class's reported long half-lives and high brain penetration.
⚠ Do not drive or operate machinery until all residual sedation and cognitive impairment have fully resolved, which may take 12 hours or longer.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · fentanyl · hydromorphone
Toxicity
Acute toxicity
Brorphine's primary acute danger is respiratory depression — the mechanism behind opioid overdose death. No lethal dose has been established in any species. Animal studies confirm it ranks among the most respiratory-depressant compounds tested in its class.[6]
For some compounds in the piperidine benzimidazolone class, high-dose naloxone could not fully reverse respiratory depression.[6] Emergency patients exposed to brorphine-class opioids required a mean of 1.33 naloxone doses compared to 0.36 for fentanyl-only patients (P = 0.02).[20] Standard naloxone dosing developed for fentanyl and heroin overdose may be insufficient.
Fatality data
Brorphine has been linked to over 100 deaths in 2020 alone,[11] with a single US laboratory documenting 91 brorphine-positive postmortem blood samples between 2020 and 2021.[21] Every documented death involved polydrug exposure — 100% with fentanyl, 80% with flualprazolam.[7] No death has been attributed to brorphine alone.
Genotoxicity
Brorphine did not produce genotoxic effects in laboratory cell testing, unlike three of its halogenated analogues (fluorphine, chlorphine, iodorphine).[22]
Organ toxicity
No organ-specific toxicity studies have been published. The primary organ risk is oxygen deprivation from respiratory depression, which can damage the brain, heart, and kidneys.
Psychological risks
As a high-efficacy opioid with a maximum receptor effect more than 2.6-fold greater than hydromorphone,[2] brorphine carries presumptive high risk for addiction, compulsive redosing, and acute cognitive impairment.inferred One clinical case — a patient seeking detoxification[17] — confirms that dependence develops in humans, but the severity and character of psychological distress have not been described.
Tolerance and dependence
Tolerance develops through standard opioid mechanisms: repeated receptor activation makes the receptor less responsive, requiring escalating doses. Cross-tolerance with morphine, Fentanyl, Hydromorphone, and methadone is expected.inferred
Physical dependence is presumed high. One clinical case confirms dependence develops in humans.[17] Withdrawal is expected to follow the standard opioid pattern — muscle pain, insomnia, sweating, nausea, anxiety, and rapid heart rate — with no published timeline specific to brorphine.inferred
Drug interactions
CNS depressant synergy
Combination with any CNS depressant produces additive or synergistic respiratory depression. Fentanyl was co-detected in 100% of forensic cases;[7] flualprazolam in 80%.[7] Adding a benzodiazepine to an opioid dramatically increases overdose mortality.[23] Alcohol also adds to CNS and respiratory depression.inferred
Opioid antagonists
Naloxone reverses brorphine's effects but may require higher or repeated doses for full reversal.[6][20]
MAOIs
No published interaction data exist. By opioid class precedent, the combination risks dangerous blood pressure changes and possibly serotonin syndrome. The specific risk for brorphine is uncharacterized.inferred
Contraindications
No substance-specific contraindication data have been published. Based on opioid pharmacology:
- Respiratory compromise: Any pre-existing breathing difficulty (COPD, sleep apnea, acute asthma) is an absolute contraindication, compounded by the documented difficulty of naloxone reversal.[6]
- Concurrent CNS depressant use: Co-use with benzodiazepines, other opioids, or alcohol is an absolute contraindication, supported by forensic mortality data.[7]
- Head injury: Opioids mask neurological warning signs and may worsen brain swelling.inferred
- Severe liver impairment: May impair drug clearance and prolong exposure.inferred
- Pregnancy: Opioid exposure during pregnancy produces neonatal withdrawal syndrome.inferred
- MAOI co-administration: Risk of unpredictable blood pressure or serotonin interactions.inferred
Harm Reduction[edit]
Forms & Identification
Brorphine is invisible to the most widely available drug checking tools. Standard fentanyl test strips and immunoassay opioid panels do not detect it — the piperidine benzimidazolone structure falls outside the antibody recognition range of tests designed for fentanyl and morphine. A negative fentanyl test result does not rule out brorphine or similar novel synthetic opioids.
The only reliable method for confirming brorphine is laboratory mass spectrometry, available through some drug checking services and harm reduction organizations. Where drug checking is accessible, submitting samples for full analytical screening provides the most complete picture of what a supply contains.
Guidelines
- Never use alone. A sober observer with naloxone access can intervene if breathing stops.
- Start with the smallest possible test dose when using any new batch of unregulated supply. Brorphine's potency is roughly ten times that of morphine — small variations in concentration produce large changes in effect.
- Have multiple doses of naloxone immediately accessible. Evidence indicates brorphine-class opioids may require more naloxone than fentanyl overdoses.[20]
- Avoid mixing with any other depressant — benzodiazepines, alcohol, or other opioids. Every documented death involved polydrug use.[7]
- Use drug checking services where available to identify what is actually in a sample.
Set & Setting
Brorphine has appeared in unregulated opioid supply mixed with fentanyl and benzodiazepines.[7] Users of unregulated opioids may encounter it without knowing. The most protective setting is the presence of a sober person with naloxone access who can recognize respiratory depression and intervene. Using alone is the highest-risk scenario for any potent opioid.
Aftercare & integration. After an opioid overdose reversal, the person should be monitored for at least 2 hours, as brorphine's effects may outlast naloxone. Withdrawal symptoms may begin rapidly after naloxone administration — muscle pain, nausea, agitation, and sweating are expected and do not require emergency intervention unless severe.
Anyone who has experienced an overdose or overdose reversal should be connected with medical follow-up. The event itself is a clinical marker of elevated future overdose risk and an opportunity to discuss treatment options including opioid agonist therapy.
Recovery & Support
Brorphine dependence, like all opioid dependence, responds to evidence-based treatment. Opioid agonist therapy with methadone or buprenorphine reduces mortality, withdrawal severity, and relapse rates. These medications stabilize the same receptors brorphine activates, without the dangerous peaks in respiratory depression.
Peer support programs and professional counseling complement medication-based treatment. Harm reduction services — including naloxone distribution, supervised consumption sites, and drug checking programs — reduce overdose death risk for people who continue to use opioids.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed to fewer than 8 breaths per minute, or stopped
- Lips, fingertips, or face turning blue or grey
- Person is unresponsive to voice or pain (sternal rub)
- Gurgling, choking, or snoring sounds while unconscious
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone (intranasal or intramuscular). If no response after 2–3 minutes, administer a second dose. Brorphine-class opioids may require multiple doses for reversal.[6]
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. Perform rescue breathing if trained and the person is not breathing.
- 5. Stay with the person — effects may return as naloxone wears off.
- 6. Do NOT leave the person alone after administering naloxone.
What to tell the dispatcher: the substance involved (if known), estimated amount, time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related charges when reporting an overdose.
Reversal agent: Naloxone reverses opioid effects but may require higher or repeated doses for brorphine-class compounds.[20] Continue monitoring even after successful reversal — naloxone's duration is shorter than brorphine's, and respiratory depression may return.
Legal Status[edit]
Brorphine is internationally controlled under Schedule I of the Single Convention on Narcotic Drugs, following WHO recommendation in October 2021[24] and formal scheduling in March 2022.[13]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule I, Single Convention on Narcotic Drugs (1961) | Scheduled March 2022 at 65th CND session[13] |
| United States | Schedule I (Controlled Substances Act) | Temporary placement March 1, 2021;[5] permanent placement March 6, 2023[12] |
| United Kingdom | Class A, Schedule 1 (Misuse of Drugs Act 1971) | ACMD recommended classification July 2022;[25] enacted via MDA 1971 Amendment Order 2024[26] |
| Canada | Schedule I, CDSA (Item 13) | Controlled under generic benzimidazole structural class definition[10] |
| Germany | Controlled (NpSG, Anlage 1) | Controlled under Neue-psychoaktive-Stoffe-Gesetz[25] |
| Australia | Controlled substance | Listed on Office of Drug Control registry; specific schedule and date not confirmed in available sourcescitation needed |
New Zealand scheduling status has not been identified in published literature or available legislative databases. citation needed
Legal status changes frequently and varies by jurisdiction. This information may not reflect the most current law in every jurisdiction. It is not legal advice.
references
- [1] ^abcVandeputte MM, Tsai MM, Chen L, Glatfelter GC, Walther D, Stove CP, Shi L, Baumann MH (2023) Comparative neuropharmacology of structurally distinct non-fentanyl opioids appearing on recreational drug markets worldwide. — Drug and Alcohol Dependence doi:10.1016/j.drugalcdep.2023.109939
- [2]
- [3]
- [4] ^abVandeputte MM, Krotulski AJ, Papsun DM, Logan BK, Stove CP (2021) The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament — Journal of Analytical Toxicology doi:10.1093/jat/bkab082
- [5]
- [6] ^abcdefghijklVandeputte MM, Bilel S, Tirri M, Corli G, Bassi M, Layle NK, Fantinati A, Walther D, Iula DM, Baumann MH, Stove CP, Marti M (2024) Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization — Neuropharmacology doi:10.1016/j.neuropharm.2024.110113